Hem › Lungcancer › Virginia › Charlottesville
Kliniska studier för Lungcancer i Charlottesville, VA
13 studier för Lungcancer söker deltagare vid platser i och runt Charlottesville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekryterarFas 3
- University of Virginia Cancer Center, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekryterarFas 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- och 1 fler
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekryterarFas 2/3
- University of Virginia Health System, Charlottesville
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RekryterarFas 1/2
- University of Virginia Cancer Center, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekryterarFas 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RekryterarFas 1/2
- University of Virginia Cancer Center, Charlottesville
The Vanguard Study: Testing a New Way to Screen for Cancer
RekryterarFriska volontärer välkomna
- Sentara Martha Jefferson Hospital, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekryterarFas 3
- University of Virginia, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekryterarFas 2
- University of Virginia Cancer Center, Charlottesville
4D-MRI for Precision Medicine
RekryterarObservationsstudieFriska volontärer välkomna
- University of Virginia, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2/3
- University of Virginia Cancer Center, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RekryterarFas 1/2
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Charlottesville
Lungcancer-studier i andra städer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Washington, DC41 studier
- Arlington, VA41 studier
- Chicago, IL41 studier
- Nashville, TN40 studier
- Baltimore, MD40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andra studier i Charlottesville
- Icke-småcellig lungcancer21 studier
- Akut myeloid leukemi16 studier
- Prostatacancer15 studier
- Metastaserande cancer13 studier
- Endometriecancer13 studier
- Cancer (alla typer)13 studier
- Hjärtsvikt11 studier
- Äggstockscancer10 studier
- Kolorektal cancer10 studier
- Typ 1-diabetes9 studier
- Bröstcancer9 studier
- Bukspottkörtelcancer9 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.